VMD Sciences opens managed access path for canine cancer therapy

CURRENT BRIEF VERSION: VMD Sciences said it helped a U.S. veterinary oncologist import and use a European-approved tyrosine kinase inhibitor for an 8-year-old dog with metastatic mast cell cancer after standard options had failed. In the January 30, 2026 announcement, the company said Dr. Seth Glasser of Garden State Veterinary Specialists in New Jersey used VMD Sciences’ managed access program to navigate documentation, customs clearance, and FDA inspection for the drug, which is approved by the European Medicines Agency but not commercially available in the U.S. The company said the dog, Jetta, had a low-grade subcutaneous mast cell tumor with lymph node metastasis, and Dr. Glasser said the medication arrived within days after VMD handled most of the process. (static1.squarespace.com)

Why it matters: For veterinary professionals, the case highlights a practical route to treatment access when approved domestic options are limited. Mast cell tumors remain one of the most common canine cancers, and U.S. clinicians already use targeted therapies such as toceranib, while Europe has additional mast cell tumor therapies available, including masitinib. At the same time, supportive care remains a major part of keeping oncology patients on treatment: Jaguar Health recently said the FDA renewed conditional approval of Canalevia-CA1 (crofelemer delayed-release tablets) through December 21, 2026 for chemotherapy-induced diarrhea in dogs, extending access to an indication-specific option aimed at reducing intestinal chloride secretion and fluid loss without slowing transit. IDEXX, meanwhile, recently said it will add canine mast cell tumor detection to its Cancer Dx Panel in mid-2026 and is rolling out in-clinic FNA cytology support, underscoring how the mast cell tumor landscape is broadening across diagnostics, treatment access, and symptom management. (pfizer.com)

What to watch: Watch for whether more specialty practices begin using managed access pathways for hard-to-treat oncology cases, whether supportive-care products like Canalevia-CA1 move from conditional to full approval, and whether sponsors move these products toward formal U.S. veterinary approval. (static1.squarespace.com)